|
DE10214983A1
(de)
|
2002-04-04 |
2004-04-08 |
TransMIT Gesellschaft für Technologietransfer mbH |
Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
|
|
DE60334618D1
(de)
|
2002-06-28 |
2010-12-02 |
Protiva Biotherapeutics Inc |
Verfahren und vorrichtung zur herstellung von liposomen
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
EP2899278A1
(en)
|
2004-03-12 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
iRNA agents targeting VEGF
|
|
AU2005306533B2
(en)
*
|
2004-11-17 |
2012-05-31 |
Arbutus Biopharma Corporation |
siRNA silencing of apolipoprotein B
|
|
US9393315B2
(en)
|
2011-06-08 |
2016-07-19 |
Nitto Denko Corporation |
Compounds for targeting drug delivery and enhancing siRNA activity
|
|
TR201909609T4
(tr)
|
2005-08-23 |
2019-07-22 |
Univ Pennsylvania |
Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri.
|
|
WO2007051303A1
(en)
|
2005-11-02 |
2007-05-10 |
Protiva Biotherapeutics, Inc. |
MODIFIED siRNA MOLECULES AND USES THEREOF
|
|
SG171676A1
(en)
|
2006-05-11 |
2011-06-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the pcsk9 gene
|
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
WO2009082817A1
(en)
*
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
|
MX2010008394A
(es)
*
|
2008-01-31 |
2010-11-12 |
Alnylam Pharmaceuticals Inc |
Metodos optimizados para administracion de arndc focalizando el gen pcsk9.
|
|
SG188121A1
(en)
*
|
2008-03-05 |
2013-03-28 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
|
DK2299953T3
(en)
|
2008-07-14 |
2017-06-19 |
Polypid Ltd |
CARBON COMPOSITION FOR MEDICINAL PRODUCTS WITH CONTINUOUS EXPOSURE
|
|
EP3584320A1
(en)
|
2008-09-25 |
2019-12-25 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
|
EP2743265B1
(en)
|
2008-10-09 |
2017-03-15 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
DK2344639T3
(en)
|
2008-10-20 |
2015-07-27 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETINE
|
|
CA3029724A1
(en)
|
2008-11-10 |
2010-05-14 |
Muthiah Manoharan |
Lipids and compositions for the delivery of therapeutics
|
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
|
JP5793423B2
(ja)
*
|
2008-12-31 |
2015-10-14 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
急性冠症候群の治療のためのLNAApoBアンチセンスオリゴマーの使用
|
|
EP2406376A1
(en)
*
|
2009-03-12 |
2012-01-18 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
|
KR101184928B1
(ko)
*
|
2009-05-14 |
2012-09-20 |
한국과학기술연구원 |
작은 올리고뉴클레오티드의 중합 방법 및 상기 중합 방법에 의하여 제조된 고분자 올리고뉴클레오티드의 용도
|
|
KR20120050429A
(ko)
*
|
2009-06-15 |
2012-05-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Pcsk9 유전자를 표적으로 하는 지질 제형된 dsrna
|
|
WO2010147992A1
(en)
*
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
DE102009031274A1
(de)
|
2009-06-30 |
2011-01-13 |
Justus-Liebig-Universität Giessen |
Liposomen zur pulmonalen Applikation
|
|
WO2011000107A1
(en)
*
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
EP2449106B1
(en)
*
|
2009-07-01 |
2015-04-08 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
CA2767973C
(en)
|
2009-07-14 |
2019-06-18 |
Polypid Ltd. |
Lipid-based sustained-release drug carrier matrix
|
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
|
AP3574A
(en)
|
2009-08-14 |
2016-02-08 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
ES2579936T3
(es)
|
2009-08-20 |
2016-08-17 |
Sirna Therapeutics, Inc. |
Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
|
|
WO2011034798A1
(en)
|
2009-09-15 |
2011-03-24 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
WO2011038031A1
(en)
|
2009-09-22 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting sirna agents
|
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
EP2496238A4
(en)
|
2009-11-03 |
2013-10-02 |
Alnylam Pharmaceuticals Inc |
FORMULATED LIPID COMPOSITIONS AND METHODS FOR INHIBITING TRANSTHYRETIN EXPRESSION (TTR)
|
|
EP2496700B1
(en)
|
2009-11-04 |
2017-03-01 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
|
RS58405B1
(sr)
|
2009-12-01 |
2019-04-30 |
Translate Bio Inc |
Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima
|
|
US8795726B2
(en)
|
2010-01-19 |
2014-08-05 |
Polypid Ltd. |
Sustained-release nucleic acid matrix compositions
|
|
JP2013523162A
(ja)
|
2010-04-06 |
2013-06-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Cd274/pd−l1遺伝子の発現を阻害するための組成物および方法
|
|
WO2011127255A1
(en)
|
2010-04-08 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
Preparation of lipid nanoparticles
|
|
WO2011139911A2
(en)
*
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
US8865675B2
(en)
|
2010-05-12 |
2014-10-21 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein B
|
|
JP2013527856A
(ja)
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
WO2011149733A2
(en)
|
2010-05-24 |
2011-12-01 |
Merck Sharp & Dohme Corp. |
Novel amino alcohol cationic lipids for oligonucleotide delivery
|
|
AU2011261434B2
(en)
|
2010-06-02 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
US10487332B2
(en)
|
2010-07-06 |
2019-11-26 |
Glaxosmithkline Biologicals Sa |
Immunisation of large mammals with low doses of RNA
|
|
EP2590625B1
(en)
*
|
2010-07-06 |
2017-09-20 |
GlaxoSmithKline Biologicals SA |
Cationic oil-in-water emulsions
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
ES2557382T3
(es)
|
2010-07-06 |
2016-01-25 |
Glaxosmithkline Biologicals Sa |
Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
|
|
MX342608B
(es)
|
2010-07-06 |
2016-10-06 |
Novartis Ag * |
Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
LT2606134T
(lt)
|
2010-08-17 |
2019-07-25 |
Sirna Therapeutics, Inc. |
Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
|
|
EP2609106A4
(en)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
ES2908978T3
(es)
|
2010-08-31 |
2022-05-04 |
Sirna Therapeutics Inc |
Nuevas entidades químicas simples y métodos para la administración de oligonucleótidos
|
|
RS63984B1
(sr)
|
2010-08-31 |
2023-03-31 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
RS63367B1
(sr)
|
2010-08-31 |
2022-07-29 |
Glaxosmithkline Biologicals Sa |
Pegilovani lipozomi za isporuku rnk koja kodira imunogen
|
|
KR101223483B1
(ko)
*
|
2010-09-10 |
2013-01-17 |
한국과학기술연구원 |
전하결합 및 생분해성 공유결합으로 동시에 연결된 고분자―siRNA 나노입자 전달체
|
|
US9669097B2
(en)
|
2010-09-20 |
2017-06-06 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
EP2621480B1
(en)
|
2010-09-30 |
2018-08-15 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
LT4108671T
(lt)
|
2010-10-01 |
2025-01-10 |
Modernatx, Inc. |
Modifikuoti nukleozidai, nukleotidai, nukleorūgštys bei jų panaudojimas
|
|
ES2716243T3
(es)
|
2010-10-11 |
2019-06-11 |
Glaxosmithkline Biologicals Sa |
Plataformas de suministro de antígenos
|
|
CN103153347A
(zh)
|
2010-10-21 |
2013-06-12 |
默沙东公司 |
用于寡核苷酸递送的新型低分子量阳离子脂质
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
EP2635265B1
(en)
|
2010-11-05 |
2018-04-04 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
US9127275B2
(en)
|
2010-12-10 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
|
KR102365961B1
(ko)
|
2011-03-29 |
2022-02-23 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
|
US20120301537A1
(en)
*
|
2011-05-23 |
2012-11-29 |
Delta-Fly Pharma, Inc. |
LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
|
|
US8592572B2
(en)
*
|
2011-05-23 |
2013-11-26 |
Delta-Fly Pharma, Inc. |
Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof
|
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
|
SMT201900445T1
(it)
|
2011-06-08 |
2019-09-09 |
Translate Bio Inc |
Composizione di nanoparticelle lipidiche e metodi per il rilascio di mrna
|
|
US9011903B2
(en)
|
2011-06-08 |
2015-04-21 |
Nitto Denko Corporation |
Cationic lipids for therapeutic agent delivery formulations
|
|
KR20230084331A
(ko)
|
2011-06-21 |
2023-06-12 |
알닐람 파마슈티칼스 인코포레이티드 |
아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
|
|
WO2012177906A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
EP3388068A1
(en)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Composition and methods for inhibition of expression of protein c (proc) genes
|
|
MX360782B
(es)
|
2011-06-21 |
2018-11-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
|
|
EP2723390B1
(en)
|
2011-06-23 |
2017-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
SMT202200229T1
(it)
|
2011-10-03 |
2022-07-21 |
Modernatx Inc |
Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi
|
|
US8999950B2
(en)
*
|
2011-10-05 |
2015-04-07 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing aldehyde dehydrogenase
|
|
WO2013059922A1
(en)
|
2011-10-25 |
2013-05-02 |
The University Of British Columbia |
Limit size lipid nanoparticles and related methods
|
|
US9320814B2
(en)
*
|
2011-11-01 |
2016-04-26 |
Board Of Regents Of The University Of Nebraska |
Polyplexes of hydrophobically-modified siRNA for delivery of siRNA
|
|
IN2014CN03463A
(pl)
|
2011-11-18 |
2015-10-09 |
Alnylam Pharmaceuticals Inc |
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
CA3165769A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
RU2649364C2
(ru)
|
2011-12-16 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
PT2817287T
(pt)
|
2012-02-24 |
2018-12-28 |
Arbutus Biopharma Corp |
Lípidos catiónicos trialquílicos e seus métodos de utilização
|
|
BR112014024131A2
(pt)
|
2012-03-29 |
2017-07-25 |
Shire Human Genetic Therapies |
lipídios catiônicos ionizáveis
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
AU2013243954A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
CN108949772A
(zh)
*
|
2012-04-02 |
2018-12-07 |
现代泰克斯公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
EP3434667B1
(en)
|
2012-04-19 |
2020-11-04 |
Sirna Therapeutics, Inc. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
CA2876155C
(en)
|
2012-06-08 |
2022-12-13 |
Ethris Gmbh |
Pulmonary delivery of mrna to non-lung target cells
|
|
EP3536787A1
(en)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
CN102719437A
(zh)
*
|
2012-07-11 |
2012-10-10 |
潍坊医学院 |
利用慢病毒载体介导PLK1 RNAi在治疗食管鳞癌转移中的应用
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
BR112015013105B1
(pt)
|
2012-12-05 |
2022-02-08 |
Alnylam Pharmaceuticals, Inc |
Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
|
|
DK3327127T3
(da)
|
2012-12-12 |
2021-06-28 |
Broad Inst Inc |
Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til sekvensmanipulation og terapeutiske anvendelser
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
CN105209490A
(zh)
|
2013-03-14 |
2015-12-30 |
夏尔人类遗传性治疗公司 |
用于递送mrna编码的抗体的方法和组合物
|
|
SG10201912286TA
(en)
|
2013-03-14 |
2020-02-27 |
Alnylam Pharmaceuticals Inc |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4446413A3
(en)
|
2013-03-14 |
2024-12-18 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
KR20210122917A
(ko)
|
2013-03-14 |
2021-10-12 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
|
EP2983804A4
(en)
|
2013-03-15 |
2017-03-01 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
|
EP4614148A3
(en)
|
2013-03-15 |
2025-12-17 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
US10138507B2
(en)
|
2013-03-15 |
2018-11-27 |
Modernatx, Inc. |
Manufacturing methods for production of RNA transcripts
|
|
WO2014140856A2
(en)
|
2013-03-15 |
2014-09-18 |
Graham Lord |
Mir-142 and antagonists thereof for treating disease
|
|
US10342760B2
(en)
|
2013-03-15 |
2019-07-09 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
|
US10077439B2
(en)
|
2013-03-15 |
2018-09-18 |
Modernatx, Inc. |
Removal of DNA fragments in mRNA production process
|
|
AP2015008862A0
(en)
|
2013-05-22 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
|
CN113018307A
(zh)
|
2013-05-22 |
2021-06-25 |
阿尔尼拉姆医药品有限公司 |
SERPINA1 iRNA组合物及其使用方法
|
|
AU2014281030B2
(en)
|
2013-06-17 |
2020-07-09 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
CA2915795C
(en)
|
2013-06-17 |
2021-07-13 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
|
AU2014281028B2
(en)
|
2013-06-17 |
2020-09-10 |
Massachusetts Institute Of Technology |
Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
|
|
RS62529B1
(sr)
|
2013-07-11 |
2021-11-30 |
Modernatx Inc |
Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
|
|
CA2919226C
(en)
|
2013-07-23 |
2024-05-14 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052626A1
(en)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
BR112016007255A2
(pt)
|
2013-10-03 |
2017-09-12 |
Moderna Therapeutics Inc |
polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
|
|
US10119143B2
(en)
|
2013-10-04 |
2018-11-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
EA034103B1
(ru)
|
2013-10-22 |
2019-12-27 |
Транслейт Био, Инк. |
СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
|
|
EP3060303B1
(en)
|
2013-10-22 |
2018-11-14 |
Translate Bio, Inc. |
Mrna therapy for argininosuccinate synthetase deficiency
|
|
CA2928040A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of mrna and uses thereof
|
|
JP6525435B2
(ja)
|
2013-10-22 |
2019-06-12 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
メッセンジャーrnaの送達のための脂質製剤
|
|
WO2015075557A2
(en)
|
2013-11-22 |
2015-05-28 |
Mina Alpha Limited |
C/ebp alpha compositions and methods of use
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
IL289736B2
(en)
|
2013-12-12 |
2025-09-01 |
Massachusetts Inst Technology |
Administration, use and therapeutic applications of CRISPR–Cas gene editing systems and gene editing preparations
|
|
SG10201804974RA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Compositions and Methods of Use of Crispr-Cas Systems in Nucleotide Repeat Disorders
|
|
MX382900B
(es)
|
2013-12-12 |
2025-03-13 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ÁCIDO RIBONUCLEICO DE INTERFERENCIA (ARNi) CONTRA EL COMPONENTE DEL COMPLEMENTO Y MÉTODOS PARA SU USO.
|
|
AU2014361826A1
(en)
|
2013-12-12 |
2016-06-23 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
AU2014361784A1
(en)
|
2013-12-12 |
2016-06-23 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders
|
|
AU2015217301A1
(en)
|
2014-02-11 |
2016-08-25 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
|
EP3556353A3
(en)
|
2014-02-25 |
2020-03-18 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
DK4023249T3
(da)
*
|
2014-04-23 |
2025-01-13 |
Modernatx Inc |
Nukleinsyrevacciner
|
|
EP3636742B1
(en)
|
2014-04-25 |
2025-11-05 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
CN106574268B
(zh)
|
2014-05-22 |
2021-02-05 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原(AGT)iRNA组合物及其使用方法
|
|
EP3148552B1
(en)
|
2014-05-30 |
2019-07-31 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
CA2952121A1
(en)
|
2014-06-13 |
2015-12-17 |
Childrens' Medical Center Corporation |
Products and methods to isolate mitochondria
|
|
EP3157573A4
(en)
|
2014-06-19 |
2018-02-21 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
SG11201610670WA
(en)
|
2014-06-24 |
2017-01-27 |
Shire Human Genetic Therapies |
Stereochemically enriched compositions for delivery of nucleic acids
|
|
PT3766916T
(pt)
|
2014-06-25 |
2022-11-28 |
Acuitas Therapeutics Inc |
Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
|
|
BR112016030852A2
(pt)
|
2014-07-02 |
2018-01-16 |
Shire Human Genetic Therapies |
encapsulação de rna mensageiro
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
JP6778175B2
(ja)
*
|
2014-07-16 |
2020-10-28 |
ノバルティス アーゲー |
脂質ナノ粒子ホスト中に核酸を封入する方法
|
|
US10407683B2
(en)
|
2014-07-16 |
2019-09-10 |
Modernatx, Inc. |
Circular polynucleotides
|
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
EP3180426B1
(en)
|
2014-08-17 |
2019-12-25 |
The Broad Institute, Inc. |
Genome editing using cas9 nickases
|
|
US9765333B2
(en)
|
2014-08-21 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing marburg virus gene expression
|
|
PL3185957T3
(pl)
*
|
2014-08-29 |
2022-11-14 |
Alnylam Pharmaceuticals, Inc. |
Patisiran do zastosowania w leczeniu amyloidozy związanej z transtyretyną
|
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
AU2015328012A1
(en)
|
2014-10-02 |
2017-05-11 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing Hepatitis B virus gene expression
|
|
TWI755351B
(zh)
|
2014-10-10 |
2022-02-21 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
HRP20192177T1
(hr)
|
2014-11-10 |
2020-02-21 |
Alnylam Pharmaceuticals, Inc. |
Rnai pripravci za virus hepatitisa b (hbv) i postupci njihove upotrebe
|
|
CN113846101A
(zh)
|
2014-11-17 |
2021-12-28 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
|
JP6767976B2
(ja)
|
2014-12-05 |
2020-10-14 |
トランスレイト バイオ, インコーポレイテッド |
関節疾患の治療のためのメッセンジャーrna治療法
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3234141A4
(en)
|
2014-12-18 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
WO2016100974A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
|
US11219634B2
(en)
|
2015-01-21 |
2022-01-11 |
Genevant Sciences Gmbh |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
|
JP6895892B2
(ja)
|
2015-03-19 |
2021-06-30 |
トランスレイト バイオ, インコーポレイテッド |
ポンペ病のmRNA治療
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
US10653768B2
(en)
|
2015-04-13 |
2020-05-19 |
Curevac Real Estate Gmbh |
Method for producing RNA compositions
|
|
CN104997801A
(zh)
*
|
2015-05-28 |
2015-10-28 |
厦门成坤生物技术有限公司 |
包含季铵盐类化合物和siRNA的组合物及其制备方法
|
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
IL293323B2
(en)
|
2015-06-18 |
2024-01-01 |
Massachusetts Inst Technology |
Crispr enzyme mutations reducing off-target effects
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
FI3430134T3
(fi)
|
2015-06-18 |
2023-01-13 |
|
Uusia CRISPR-entsyymejä ja järjestelmiä
|
|
WO2016205745A2
(en)
*
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
HRP20240865T1
(hr)
|
2015-06-29 |
2024-10-11 |
Acuitas Therapeutics Inc. |
Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
|
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
|
AU2016291597B2
(en)
*
|
2015-07-10 |
2021-01-14 |
Peptinovo Biopharma, Llc |
Formulations for improving the efficacy of hydrophobic drugs
|
|
EP3324979B1
(en)
|
2015-07-21 |
2022-10-12 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
CN108350455A
(zh)
|
2015-07-29 |
2018-07-31 |
阿布特斯生物制药公司 |
用于使b型肝炎病毒基因表达沉默的组合物和方法
|
|
MA42543A
(fr)
|
2015-07-30 |
2018-06-06 |
Modernatx Inc |
Arn épitope peptidiques concatémériques
|
|
DK3329002T3
(da)
|
2015-07-31 |
2021-01-11 |
Alnylam Pharmaceuticals Inc |
Transthyretin (ttr)-irna-sammensætninger og fremgangsmåder til anvendelse deraf til behandling eller forebyggelse af ttr-forbundne sygdomme
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP3337908A4
(en)
|
2015-08-18 |
2019-01-23 |
The Broad Institute, Inc. |
METHOD AND COMPOSITIONS FOR CHANGING THE FUNCTION AND STRUCTURE OF CHROMATIN GRINDING AND / OR DOMAINS
|
|
EP3340967B1
(en)
|
2015-08-24 |
2024-05-22 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
EP4393495A3
(en)
|
2015-09-02 |
2024-09-25 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
|
|
EP3350328A1
(en)
|
2015-09-14 |
2018-07-25 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
DK3350333T3
(da)
|
2015-09-17 |
2022-01-31 |
Modernatx Inc |
Polynukleotider, der indeholder en stabiliserende haleregion
|
|
ES2910425T3
(es)
|
2015-09-17 |
2022-05-12 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
|
US11434486B2
(en)
|
2015-09-17 |
2022-09-06 |
Modernatx, Inc. |
Polynucleotides containing a morpholino linker
|
|
ES2810701T5
(es)
|
2015-10-05 |
2024-07-11 |
Modernatx Inc |
Procedimientos para la administración terapéutica de medicamentos de ácido ribonucleico mensajero
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
ES2862412T3
(es)
|
2015-10-14 |
2021-10-07 |
Translate Bio Inc |
Modificación de enzimas relacionados con el ARN para producción mejorada
|
|
ES3036518T3
(en)
|
2015-10-16 |
2025-09-19 |
Ipsen Biopharm Ltd |
Stabilizing camptothecin pharmaceutical compositions
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
JP6925688B2
(ja)
|
2015-10-22 |
2021-08-25 |
モデルナティーエックス, インコーポレイテッド |
水痘帯状疱疹ウイルス(vzv)のための核酸ワクチン
|
|
WO2017070613A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3003090A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Cancer vaccines
|
|
CN109153980B
(zh)
|
2015-10-22 |
2023-04-14 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
|
JP2018531290A
(ja)
|
2015-10-22 |
2018-10-25 |
モデルナティーエックス, インコーポレイテッド |
性感染症ワクチン
|
|
EP3368687B1
(en)
|
2015-10-27 |
2021-09-29 |
The Broad Institute, Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075531A1
(en)
|
2015-10-28 |
2017-05-04 |
Acuitas Therapeutics, Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11903974B2
(en)
|
2015-11-30 |
2024-02-20 |
Flagship Pioneering Innovations V, Inc. |
Methods and compositions relating to chondrisomes from cultured cells
|
|
AU2016366978B2
(en)
|
2015-12-10 |
2022-07-28 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
CA3007297A1
(en)
|
2015-12-22 |
2017-06-29 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP4039699A1
(en)
|
2015-12-23 |
2022-08-10 |
ModernaTX, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
|
EP3400023A1
(en)
|
2016-01-10 |
2018-11-14 |
ModernaTX, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
DK4272834T3
(da)
|
2016-01-15 |
2025-12-15 |
Childrens Medical Ct Corp |
Terapeutisk anvendelse af mitokondrier og kombinerede mitokondrielle midler
|
|
KR102369898B1
(ko)
|
2016-04-08 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
다량체 코딩 핵산 및 그 용도
|
|
EP3445856A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
AU2017253089B2
(en)
|
2016-04-19 |
2023-07-20 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
RS63912B1
(sr)
|
2016-05-18 |
2023-02-28 |
Modernatx Inc |
Polinukleotidi koji kodiraju interleukin-12 (il12) i njihove upotrebe
|
|
EP3458474B1
(en)
*
|
2016-05-18 |
2022-07-06 |
ModernaTX, Inc. |
Combinations of mrnas encoding immune modulating polypeptides and uses thereof
|
|
JP7088911B2
(ja)
|
2016-05-18 |
2022-06-21 |
モデルナティエックス インコーポレイテッド |
リラキシンをコードするポリヌクレオチド
|
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
EP3842530A1
(en)
|
2016-06-13 |
2021-06-30 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
|
|
AU2017286606A1
(en)
*
|
2016-06-14 |
2018-12-13 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
KR20190019168A
(ko)
|
2016-06-17 |
2019-02-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
제vi형 crispr 오솔로그 및 시스템
|
|
WO2017223176A1
(en)
|
2016-06-24 |
2017-12-28 |
Modernatx, Inc. |
Methods and apparatus for filtration
|
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
|
MX2018016389A
(es)
|
2016-06-30 |
2019-08-16 |
Arbutus Biopharma Corp |
Composiciones y metodos para suministro de arn mensajero.
|
|
AU2017293931A1
(en)
|
2016-07-07 |
2019-01-17 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems expressing exogenous RNA
|
|
US11352647B2
(en)
|
2016-08-17 |
2022-06-07 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
US20200283743A1
(en)
|
2016-08-17 |
2020-09-10 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
SG10201913631TA
(en)
|
2016-08-19 |
2020-03-30 |
Curevac Ag |
Rna for cancer therapy
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
EP3519578B1
(en)
|
2016-10-03 |
2021-12-22 |
Precision Nanosystems Inc |
Compositions for transfecting resistant cell types
|
|
WO2018119514A1
(en)
*
|
2016-12-28 |
2018-07-05 |
Precision Nanosystems Inc. |
Compositions for transfecting resistant cell types
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
DK3532103T3
(da)
|
2016-10-26 |
2026-03-02 |
Acuitas Therapeutics Inc |
Formuleringer af lipid-nanopartikler
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN110167587A
(zh)
|
2016-11-11 |
2019-08-23 |
摩登纳特斯有限公司 |
流感疫苗
|
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
EP3551230A1
(en)
|
2016-12-08 |
2019-10-16 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
EP3558356A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Mers coronavirus vaccine
|
|
AU2018224326B2
(en)
|
2017-02-27 |
2024-01-04 |
Translate Bio, Inc. |
Novel codon-optimized CFTR mRNA
|
|
WO2018170256A1
(en)
*
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
US11739308B2
(en)
|
2017-03-15 |
2023-08-29 |
The Broad Institute, Inc. |
Cas13b orthologues CRISPR enzymes and systems
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
EP3596042B1
(en)
|
2017-03-15 |
2022-01-12 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
JP2020514370A
(ja)
|
2017-03-17 |
2020-05-21 |
キュアバック アーゲー |
組合せ抗癌療法のためのrnaワクチン及び免疫チェックポイント阻害剤
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
US11338045B2
(en)
|
2017-03-17 |
2022-05-24 |
Newcastle University |
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
|
|
CN110914433A
(zh)
|
2017-03-24 |
2020-03-24 |
库尔维科公司 |
编码crispr相关蛋白质的核酸及其用途
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
EP3610009A1
(en)
|
2017-04-12 |
2020-02-19 |
The Broad Institute, Inc. |
Novel type vi crispr orthologs and systems
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
US12350368B2
(en)
|
2017-04-14 |
2025-07-08 |
The Broad Institute, Inc. |
Delivery of large payloads
|
|
CN118384268A
(zh)
|
2017-04-18 |
2024-07-26 |
阿尔尼拉姆医药品有限公司 |
具有乙肝病毒(hbv)感染的受试者的治疗方法
|
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
ES3052812T3
(en)
|
2017-05-08 |
2026-01-14 |
Flagship Pioneering Innovations V Inc |
Compositions for facilitating membrane fusion and uses thereof
|
|
US11173190B2
(en)
|
2017-05-16 |
2021-11-16 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
|
|
WO2018213726A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
EP3630200A4
(en)
|
2017-05-31 |
2021-02-24 |
Arcturus Therapeutics, Inc. |
THERAPEUTICS FOR PHENYLKETONURIA
|
|
EP3630985B1
(en)
|
2017-05-31 |
2025-08-27 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency rna therapeutics
|
|
KR102636537B1
(ko)
|
2017-05-31 |
2024-02-15 |
울트라제닉스 파마수티컬 인코포레이티드 |
글리코겐 축적 질환 유형 iii에 대한 치료제
|
|
EP3638797A1
(en)
|
2017-06-13 |
2020-04-22 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising curons and uses thereof
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
EP3424524B1
(en)
|
2017-07-04 |
2024-12-11 |
CureVac SE |
Cancer rna-vaccine
|
|
EP3652317A1
(en)
|
2017-07-13 |
2020-05-20 |
Alnylam Pharmaceuticals, Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
ES2997124T3
(en)
|
2017-08-17 |
2025-02-14 |
Acuitas Therapeutics Inc |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US20190062788A1
(en)
|
2017-08-22 |
2019-02-28 |
Rubius Therapeutics, Inc. |
Lipid nanoparticle methods and compositions for producing engineered erythroid cells
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
US11447773B2
(en)
|
2017-09-08 |
2022-09-20 |
Mina Therapeutics Limited |
Stabilized HNF4A saRNA compositions and methods of use
|
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
US11806360B2
(en)
|
2017-09-19 |
2023-11-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
|
|
WO2019060746A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
SYSTEMS, METHODS, AND COMPOSITIONS FOR THE TARGETED EDITING OF NUCLEIC ACIDS
|
|
EP3692152B1
(en)
|
2017-10-04 |
2025-09-03 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
IL321714A
(en)
|
2017-10-19 |
2025-08-01 |
CureVac SE |
Novel artificial nucleic acid molecules
|
|
US12227742B2
(en)
|
2017-10-23 |
2025-02-18 |
The Broad Institute, Inc. |
Nucleic acid modifiers
|
|
US11547614B2
(en)
|
2017-10-31 |
2023-01-10 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
EP3710587A1
(en)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
EP3714054A1
(en)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
US11931406B2
(en)
|
2017-12-13 |
2024-03-19 |
CureVac SE |
Flavivirus vaccine
|
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
|
JP2021508491A
(ja)
|
2017-12-18 |
2021-03-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
高移動度グループボックス−1(HMGB1)iRNA組成物及びその使用方法
|
|
MA51306A
(fr)
|
2017-12-20 |
2020-10-28 |
Translate Bio Inc |
Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
|
|
WO2019126709A1
(en)
|
2017-12-22 |
2019-06-27 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
IL275567B2
(en)
*
|
2017-12-27 |
2024-03-01 |
Takeda Pharmaceuticals Co |
Nucleic acid-containing lipid nano-particle and use thereof
|
|
EP3737408A1
(en)
|
2018-01-08 |
2020-11-18 |
Novartis AG |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
US20190330591A1
(en)
|
2018-01-10 |
2019-10-31 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
|
EP3746090A4
(en)
|
2018-01-29 |
2021-11-17 |
ModernaTX, Inc. |
RSV RNA Vaccines
|
|
US20190269728A1
(en)
|
2018-03-02 |
2019-09-05 |
Sixfold Bioscience Ltd. |
Compositions for delivery of cargo to cells
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
AU2019252680B2
(en)
|
2018-04-12 |
2025-11-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
|
EP4227319B1
(en)
|
2018-04-17 |
2025-11-26 |
CureVac SE |
Novel rsv rna molecules and compositions for vaccination
|
|
JP7427608B2
(ja)
|
2018-05-11 |
2024-02-05 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその使用方法
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
|
JP7178409B2
(ja)
|
2018-06-08 |
2022-11-25 |
富士フイルム株式会社 |
化合物またはその塩および脂質粒子
|
|
DK3807413T3
(da)
|
2018-06-18 |
2025-08-25 |
Res Inst Nationwide Childrens Hospital |
Adenoassocieret virusvektorfremføring af muskelspecifik mikrodystrofin til behandling af muskeldystrofi
|
|
US12357580B2
(en)
|
2018-06-19 |
2025-07-15 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
|
US20210163944A1
(en)
|
2018-08-07 |
2021-06-03 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
|
EP3837367A1
(en)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
|
JP7425066B2
(ja)
|
2018-09-04 |
2024-01-30 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
核酸を臓器特異的送達するための組成物および方法
|
|
GB2592504B
(en)
|
2018-09-04 |
2023-02-15 |
Univ Texas |
Compositions and methods for organ specific delivery of nucleic acids
|
|
CN118667811A
(zh)
|
2018-09-18 |
2024-09-20 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
|
JP7410135B2
(ja)
|
2018-09-19 |
2024-01-09 |
モデルナティエックス インコーポレイテッド |
治療薬の細胞内送達のための化合物及び組成物
|
|
WO2020061284A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
EP3853305B1
(en)
|
2018-09-19 |
2024-10-02 |
ModernaTX, Inc. |
High-purity peg lipids and uses thereof
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
CA3113449A1
(en)
|
2018-09-21 |
2020-03-26 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
KR20210068093A
(ko)
|
2018-09-28 |
2021-06-08 |
넛크래커 테라퓨틱스 인코포레이티드 |
핵산 전달을 위한 지질화 양이온성 펩타이드 화합물을 포함하는 지질 나노입자 제형
|
|
CN118307422A
(zh)
*
|
2018-10-01 |
2024-07-09 |
阿尔尼拉姆医药品有限公司 |
用于递送活性剂的可生物降解脂质
|
|
US11980673B2
(en)
|
2018-10-09 |
2024-05-14 |
The University Of British Columbia |
Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
|
|
AU2019361129A1
(en)
|
2018-10-18 |
2021-05-20 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
EP3876999A4
(en)
|
2018-11-09 |
2022-08-31 |
Arbutus Biopharma Corporation |
NEGATIVELY CHARGED PEG-LIPID CONJUGATES
|
|
JP2022506956A
(ja)
|
2018-11-09 |
2022-01-17 |
アルブータス・バイオファーマー・コーポレイション |
脂質ナノ粒子製剤
|
|
AU2019376006A1
(en)
|
2018-11-09 |
2021-06-03 |
Arbutus Biopharma Corporation |
Cationic lipids containing silicon
|
|
AU2019384557B2
(en)
|
2018-11-21 |
2025-07-17 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
|
US12485136B2
(en)
|
2018-12-03 |
2025-12-02 |
Takeda Pharmaceuticals U.S.A., Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity
|
|
CA3122080A1
(en)
|
2018-12-06 |
2020-06-11 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
|
US12268669B2
(en)
|
2018-12-20 |
2025-04-08 |
Pfizer Inc. |
Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
|
|
WO2020128031A2
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Rna for malaria vaccines
|
|
US12042527B2
(en)
|
2019-01-08 |
2024-07-23 |
Modernatx, Inc. |
Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
US12534714B2
(en)
|
2019-03-18 |
2026-01-27 |
The Broad Institute, Inc. |
Type VII CRISPR proteins and systems
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
JP7744011B2
(ja)
|
2019-06-07 |
2025-09-25 |
スクライブ・セラピューティクス・インコーポレイテッド |
操作されたcasxシステム
|
|
JP7241869B2
(ja)
|
2019-06-07 |
2023-03-17 |
富士フイルム株式会社 |
脂質組成物
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
JP7759311B2
(ja)
|
2019-07-19 |
2025-10-23 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
リコンビナーゼ組成物及び使用方法
|
|
CN114502542A
(zh)
|
2019-07-29 |
2022-05-13 |
佐治亚技术研究公司 |
包含限制性脂质的纳米材料及其用途
|
|
WO2021020412A1
(ja)
|
2019-07-30 |
2021-02-04 |
塩野義製薬株式会社 |
Murf1を標的とする核酸医薬
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4007812A1
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof
|
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
AU2020328855A1
(en)
|
2019-08-14 |
2022-03-03 |
CureVac SE |
RNA combinations and compositions with decreased immunostimulatory properties
|
|
UA129330C2
(uk)
|
2019-08-14 |
2025-03-19 |
Акітас Терап'Ютікс, Інк. |
Поліпшені ліпідні наночастинки для доставляння нуклеїнових кислот
|
|
KR20220047826A
(ko)
|
2019-08-16 |
2022-04-19 |
리제너론 파마슈티칼스 인코포레이티드 |
고 농도의 항-c5 제형
|
|
WO2021053405A2
(en)
|
2019-08-30 |
2021-03-25 |
Sixfold Bioscience Ltd. |
Compositions for transfer of cargo to cells
|
|
CN114616331B
(zh)
|
2019-09-03 |
2024-10-22 |
阿尔尼拉姆医药品有限公司 |
抑制lect2基因表达的组合物和方法
|
|
CN114929205B
(zh)
|
2019-09-06 |
2024-09-03 |
世代生物公司 |
包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
|
|
CA3154618A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
|
JP7676377B2
(ja)
|
2019-10-22 |
2025-05-14 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体成分C3 iRNA組成物およびその使用方法
|
|
KR20220087537A
(ko)
|
2019-10-25 |
2022-06-24 |
리제너론 파아마슈티컬스, 인크. |
C5 관련 질환을 치료 또는 예방하기 위한 투여 요법
|
|
CN119499394A
(zh)
|
2019-11-01 |
2025-02-25 |
阿尔尼拉姆医药品有限公司 |
亨廷顿(HTT)iRNA药剂组合物及其使用方法
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
WO2021096763A1
(en)
|
2019-11-13 |
2021-05-20 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
|
DK4328309T3
(da)
|
2019-11-15 |
2025-08-18 |
Fujifilm Corp |
Lipidsammensætning
|
|
CR20220220A
(es)
|
2019-11-18 |
2022-09-20 |
Janssen Biotech Inc |
Vacunas basadas en calr y jak2 mutantes y sus usos
|
|
AU2020385378A1
(en)
|
2019-11-22 |
2022-04-07 |
Generation Bio Co. |
Ionizable lipids and nanoparticle compositions thereof
|
|
EP4061945A1
(en)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
CA3164599A1
(en)
|
2019-12-13 |
2021-06-17 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法
|
|
EP4076647A1
(en)
|
2019-12-20 |
2022-10-26 |
CureVac AG |
Lipid nanoparticles for delivery of nucleic acids
|
|
KR20220123536A
(ko)
|
2020-01-09 |
2022-09-07 |
가이드 테라퓨틱스 엘엘씨 |
나노물질
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
DE202021003575U1
(de)
|
2020-02-04 |
2022-01-17 |
Curevac Ag |
Coronavirus-Vakzine
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
MX2022009763A
(es)
|
2020-02-10 |
2022-09-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
|
|
KR20220143106A
(ko)
|
2020-02-18 |
2022-10-24 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 C3 (APOC3) iRNA 조성물 및 이의 사용 방법
|
|
US12351834B2
(en)
|
2020-03-03 |
2025-07-08 |
Arcturus Therapeutics, Inc. |
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
|
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
BR112022017822A2
(pt)
|
2020-03-06 |
2022-11-08 |
Alnylam Pharmaceuticals Inc |
Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas
|
|
EP4117725A4
(en)
|
2020-03-09 |
2024-05-29 |
Arcturus Therapeutics, Inc. |
CORONAVIRUS VACCINE METHODS AND COMPOSITIONS
|
|
US20230134550A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
CA3172572A1
(en)
|
2020-03-24 |
2021-09-30 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
CN116209759A
(zh)
|
2020-03-26 |
2023-06-02 |
阿尔尼拉姆医药品有限公司 |
冠状病毒iRNA组合物及其使用方法
|
|
IL296763B1
(en)
|
2020-03-27 |
2025-12-01 |
Generation Bio Co |
Novel lipids and nanoparticle compositions thereof
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
AU2021250814A1
(en)
|
2020-03-30 |
2022-10-13 |
BioNTech SE |
RNA compositions targeting Claudin-18.2
|
|
US12534731B2
(en)
|
2020-04-01 |
2026-01-27 |
Alnylam Pharmaceuticals, Inc. |
Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
|
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
|
MX2022012493A
(es)
|
2020-04-06 |
2022-10-27 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc).
|
|
AU2021251754A1
(en)
|
2020-04-07 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing SCN9A expression
|
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4133077A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
AU2021252164A1
(en)
|
2020-04-09 |
2022-12-15 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
|
JP2023522249A
(ja)
*
|
2020-04-22 |
2023-05-29 |
ビオンテック・ソシエタス・エウロパエア |
コロナウイルスワクチン
|
|
AU2021263554A1
(en)
|
2020-04-27 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein E (APOE) iRNA agent compositions and methods of use thereof
|
|
US11357865B2
(en)
|
2020-04-27 |
2022-06-14 |
Sixfold Bioscience Ltd. |
Compositions containing nucleic acid nanoparticles with modular functionality
|
|
KR20230017789A
(ko)
|
2020-04-30 |
2023-02-06 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
|
|
US12070509B2
(en)
|
2020-05-01 |
2024-08-27 |
Arcturus Therapeutics, Inc. |
Nucleic acids and methods of treatment for cystic fibrosis
|
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150087A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
MX2022014653A
(es)
|
2020-05-20 |
2023-02-16 |
Flagship Pioneering Innovations Vi Llc |
Composiciones de antigeno de coronavirus y sus usos.
|
|
CA3179444A1
(en)
|
2020-05-20 |
2021-11-25 |
Avak Kahvejian |
Immunogenic compositions and uses thereof
|
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
WO2021243301A2
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
US20230203510A1
(en)
|
2020-05-29 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
|
BR112022024248A2
(pt)
|
2020-05-29 |
2023-10-10 |
CureVac SE |
Vacinas de combinação à base de ácido nucleico
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
WO2021252649A2
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
|
|
MX2022016332A
(es)
|
2020-06-15 |
2023-04-03 |
Res Inst Nationwide Childrens Hospital |
Administracion de vectores de virus adenoasociados para distrofias musculares.
|
|
BR112022024420A2
(pt)
|
2020-06-18 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
US12295997B2
(en)
|
2020-07-06 |
2025-05-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
CN116367854A
(zh)
|
2020-07-08 |
2023-06-30 |
杨森科学爱尔兰无限公司 |
针对hbv的rna复制子疫苗
|
|
JP2023534206A
(ja)
*
|
2020-07-10 |
2023-08-08 |
ジェネヴァント サイエンシズ ゲーエムベーハー |
肺に治療薬を送達するための脂質ナノ粒子
|
|
BR112023000327A2
(pt)
|
2020-07-16 |
2023-01-31 |
Acuitas Therapeutics Inc |
Lipídeos catiônicos para o uso em nanopartículas lipídicas
|
|
EP4189098A1
(en)
|
2020-07-27 |
2023-06-07 |
Anjarium Biosciences AG |
Compositions of dna molecules, methods of making therefor, and methods of use thereof
|
|
US20230272052A1
(en)
|
2020-07-31 |
2023-08-31 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
US12178921B2
(en)
|
2020-08-14 |
2024-12-31 |
Arcturus Therapeutics, Inc. |
Method of lyophilizing lipid nanoparticles
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
JP2023542492A
(ja)
|
2020-09-03 |
2023-10-10 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
免疫原性組成物及びその使用
|
|
MX2023002928A
(es)
|
2020-09-13 |
2023-06-12 |
Arcturus Therapeutics Inc |
Encapsulacion de arn grande en nanoparticulas lipidicas.
|
|
JP7518909B2
(ja)
|
2020-09-14 |
2024-07-18 |
富士フイルム株式会社 |
脂質組成物
|
|
WO2022060871A1
(en)
|
2020-09-15 |
2022-03-24 |
Verve Therapeutics, Inc. |
Lipid formulations for gene editing
|
|
TW202228784A
(zh)
|
2020-09-23 |
2022-08-01 |
奧地利商艾柏力維亞生技有限公司 |
用以於一患者中螯合非預期的抗peg抗體的化合物
|
|
CZ310613B6
(cs)
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
EP4225917A1
(en)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
|
JP2023546175A
(ja)
|
2020-10-14 |
2023-11-01 |
ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド |
脂質ナノ粒子製造の方法及びそれに由来する組成物
|
|
WO2022087041A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
EP4244355A1
(en)
|
2020-11-13 |
2023-09-20 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor v (f5) irna compositions and methods of use thereof
|
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
|
EP4256053A1
(en)
|
2020-12-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
CA3201258A1
(en)
|
2020-12-03 |
2022-06-09 |
Sean Higgins |
Engineered class 2 type v crispr systems
|
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
AU2021410666A1
(en)
|
2020-12-21 |
2023-06-29 |
Beam Therapeutics Inc. |
Nanomaterials comprising ester-linked acetals
|
|
US11918643B2
(en)
|
2020-12-22 |
2024-03-05 |
CureVac SE |
RNA vaccine against SARS-CoV-2 variants
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
JP2024500879A
(ja)
*
|
2020-12-22 |
2024-01-10 |
コーネル ユニヴァーシティー |
双性イオン性脂質ナノ粒子組成物およびその使用方法
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
AU2021409740A1
(en)
|
2020-12-23 |
2023-07-06 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
EP4019006A1
(en)
*
|
2020-12-28 |
2022-06-29 |
Industrial Technology Research Institute |
Immunostimulatory lipoplex, pharmaceutical composition including immunostimulatory lipoplex, and uses thereof
|
|
EP4267740A1
(en)
|
2020-12-28 |
2023-11-01 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
KR20230131863A
(ko)
|
2021-01-20 |
2023-09-14 |
빔 테라퓨틱스, 인크. |
나노물질
|
|
CA3203628A1
(en)
|
2021-01-20 |
2022-07-28 |
Beam Therapeutics Inc. |
Nanomaterials comprising a biodegradable feature
|
|
MX2023007788A
(es)
|
2021-01-24 |
2023-11-17 |
Michael David Forrest |
Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.
|
|
EP4087938A2
(en)
|
2021-01-27 |
2022-11-16 |
CureVac AG |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
IL304880A
(en)
|
2021-02-12 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プリオンタンパク質(prnp)irna組成物およびその使用方法
|
|
WO2022182574A1
(en)
|
2021-02-26 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
AU2022226409A1
(en)
|
2021-02-26 |
2023-08-10 |
Ethris Gmbh |
Formulations for aerosol formation and aerosols for the delivery of nucleic acid
|
|
JP2024508896A
(ja)
|
2021-03-04 |
2024-02-28 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アンジオポエチン様3(ANGPTL3)iRNA組成物およびその使用方法
|
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
WO2022200575A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
US20240175033A1
(en)
|
2021-03-26 |
2024-05-30 |
Mina Therapeutics Limited |
TMEM173 saRNA Compositions and Methods of Use
|
|
BR112023019981A2
(pt)
|
2021-03-29 |
2023-12-12 |
Alnylam Pharmaceuticals Inc |
Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4312988A2
(en)
|
2021-03-31 |
2024-02-07 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
|
EP4314293A1
(en)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
DK4319803T3
(da)
|
2021-04-08 |
2025-12-15 |
Vaxthera Sas |
Coronavirusvaccine omfattende et mosaikprotein
|
|
EP4326860A1
(en)
|
2021-04-20 |
2024-02-28 |
Anjarium Biosciences AG |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
US20240165044A1
(en)
|
2021-04-22 |
2024-05-23 |
Inventage Lab Inc. |
Lipid nanoparticle preparation method and preparation apparatus therefor
|
|
TW202309280A
(zh)
|
2021-04-26 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
跨膜絲胺酸蛋白酶6(TMPRSS6)iRNA組成物及其使用方法
|
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
CN117881786A
(zh)
|
2021-04-27 |
2024-04-12 |
世代生物公司 |
表达治疗性抗体的非病毒dna载体及其用途
|
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
EP4341401A1
(en)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022244831A1
(en)
|
2021-05-21 |
2022-11-24 |
Okinawa Institute Of Science And Technology School Corporation |
Coronavirus vaccine suitable for elderly individuals
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
JP2024522996A
(ja)
|
2021-06-02 |
2024-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
|
WO2022256290A2
(en)
|
2021-06-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
|
US20240271162A1
(en)
|
2021-06-11 |
2024-08-15 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
|
US20240269302A1
(en)
|
2021-06-11 |
2024-08-15 |
Nibec Co., Ltd. |
Nanoparticle comprising peptide-lipid conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
|
|
CN117642380A
(zh)
|
2021-06-14 |
2024-03-01 |
世代生物公司 |
阳离子脂质及其组合物
|
|
JP2024526202A
(ja)
|
2021-06-22 |
2024-07-17 |
バイオ-トリップ ベーフェー |
ナノ粒子を含有する核酸
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
JP2024527304A
(ja)
|
2021-06-30 |
2024-07-24 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アンジオテンシノーゲン(agt)関連障害を治療するための方法および組成物
|
|
EP4367237A2
(en)
|
2021-07-09 |
2024-05-15 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
WO2023288287A2
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
|
|
WO2023288288A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
|
|
WO2023288285A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Polycistronic expression vectors
|
|
JP2024526890A
(ja)
|
2021-07-21 |
2024-07-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
代謝障害関連標的遺伝子irna組成物およびその使用方法
|
|
WO2023003995A1
(en)
|
2021-07-23 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
CA3227440A1
(en)
|
2021-07-27 |
2023-02-02 |
Stand Therapeutics Co., Ltd. |
Peptide tag and nucleic acid encoding same
|
|
JP2024529437A
(ja)
|
2021-07-29 |
2024-08-06 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
3-ヒドロキシ-3-メチルグリタル-COAレダクターゼ(HMGCR)iRNA組成物およびその使用方法
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
IL310244A
(en)
|
2021-08-03 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Transthyretin (TTR) IRNA compositions and methods of using them
|
|
MX2024001445A
(es)
|
2021-08-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) y metodos para silenciar el angiotensinogeno (agt).
|
|
JP2024534766A
(ja)
|
2021-08-13 |
2024-09-26 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
第XII因子(F12)iRNA組成物およびその使用方法
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
AU2022339821A1
(en)
|
2021-08-31 |
2024-03-07 |
Alnylam Pharmaceuticals, Inc. |
Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
|
|
WO2023031392A2
(en)
|
2021-09-03 |
2023-03-09 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
JP2024538489A
(ja)
|
2021-09-03 |
2024-10-23 |
キュアバック エスイー |
核酸を送達するための新規な脂質ナノ粒子
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
EP4464783A3
(en)
|
2021-09-17 |
2025-01-22 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for producing circular polyribonucleotides
|
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
AU2022349627A1
(en)
|
2021-09-21 |
2024-03-21 |
Scribe Therapeutics Inc. |
Engineered casx repressor systems
|
|
MX2024003519A
(es)
|
2021-09-24 |
2024-04-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
|
|
EP4416284A1
(en)
|
2021-10-15 |
2024-08-21 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
|
TW202322826A
(zh)
|
2021-10-18 |
2023-06-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物及方法
|
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
JP2024541989A
(ja)
|
2021-10-29 |
2024-11-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
補体因子B(CFB)iRNA組成物およびその使用方法
|
|
US20250043269A1
(en)
|
2021-11-03 |
2025-02-06 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad |
Precise Genome Editing Using Retrons
|
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
KR102772764B1
(ko)
|
2021-11-10 |
2025-02-27 |
주식회사 에스엠엘바이오팜 |
트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
|
|
CN118829625A
(zh)
|
2021-11-16 |
2024-10-22 |
赛欧生物医药股份有限公司 |
新型可电离脂质和脂质纳米颗粒以及它们的使用方法
|
|
MX2024006134A
(es)
|
2021-11-22 |
2024-07-29 |
Sail Biomedicines Inc |
Lipidos ionizables novedosos y nanoparticulas de lipido y metodos para usar los mismos.
|
|
WO2023096990A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovation Vi, Llc |
Coronavirus immunogen compositions and their uses
|
|
KR20240125931A
(ko)
|
2021-11-24 |
2024-08-20 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
수두-대상포진 바이러스 면역원 조성물 및 이의 용도
|
|
US20250032604A1
(en)
|
2021-11-24 |
2025-01-30 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and their uses
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
IL313486A
(en)
|
2021-12-16 |
2024-08-01 |
Acuitas Therapeutics Inc |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023115013A1
(en)
|
2021-12-17 |
2023-06-22 |
Flagship Pioneering Innovations Vi, Llc |
Methods for enrichment of circular rna under denaturing conditions
|
|
WO2023121965A1
(en)
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Nanomaterial comprising diamines
|
|
EP4452942A1
(en)
|
2021-12-20 |
2024-10-30 |
Beam Therapeutics Inc. |
Nanomaterials comprising disulfides
|
|
AU2022418511A1
(en)
|
2021-12-20 |
2024-06-20 |
Beam Therapeutics Inc. |
Ionizable amine lipids and lipid nanoparticles
|
|
JP2025500824A
(ja)
|
2021-12-20 |
2025-01-15 |
ビーム セラピューティクス インク. |
四価脂質化合物を含むナノ材料
|
|
WO2023121970A1
(en)
|
2021-12-20 |
2023-06-29 |
Beam Therapeutics Inc. |
Ionizable amine and ester lipids and lipid nanoparticles
|
|
CN118679254A
(zh)
|
2021-12-22 |
2024-09-20 |
旗舰创业创新六公司 |
用于纯化多核糖核苷酸的组合物和方法
|
|
US20230201817A1
(en)
|
2021-12-23 |
2023-06-29 |
Biontech Delivery Technologies Gmbh |
Modular drug production system
|
|
MX2024007870A
(es)
|
2021-12-23 |
2024-08-15 |
Flagship Pioneering Innovations Vi Llc |
Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
JP2025504404A
(ja)
|
2022-01-14 |
2025-02-12 |
アンジャリウム バイオサイエンシズ エージー |
Viii因子をコードするdna分子の組成物、それを作製する方法、及びその使用方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
CN118660708A
(zh)
|
2022-01-25 |
2024-09-17 |
公益财团法人川崎市产业振兴财团 |
用于经皮给药的含有rna的组合物和该组合物的给药方法
|
|
IL314324A
(en)
|
2022-01-27 |
2024-09-01 |
BioNTech SE |
Pharmaceutical preparations for administration of herpes simplex virus antigens and related methods
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
JP2025508467A
(ja)
|
2022-02-24 |
2025-03-26 |
アイオー バイオテック エーピーエス |
癌治療のヌクレオチド送達
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
EP4691500A3
(en)
|
2022-03-15 |
2026-04-01 |
FUJIFILM Corporation |
Lipid composition
|
|
JP2025512763A
(ja)
|
2022-03-23 |
2025-04-22 |
ナノベーション・セラピューティクス・インコーポレイテッド |
高ステロール含有脂質ナノ粒子
|
|
CA3245624A1
(en)
|
2022-03-25 |
2023-09-28 |
Sail Biomedicines, Inc. |
NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND THEIR METHODS OF USE
|
|
JP2025512806A
(ja)
|
2022-04-01 |
2025-04-22 |
ナノベーション・セラピューティクス・インコーポレイテッド |
mRNA送達方法およびその組成物
|
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
EP4504252A2
(en)
|
2022-04-08 |
2025-02-12 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
JPWO2023199943A1
(pl)
|
2022-04-12 |
2023-10-19 |
|
|
|
CN119365208A
(zh)
|
2022-04-13 |
2025-01-24 |
巴塞罗那自治大学 |
通过表达klotho蛋白的基因疗法治疗神经肌肉疾病
|
|
AU2023260227A1
(en)
|
2022-04-27 |
2024-11-21 |
Shanghai Regenelead Therapies Co., Ltd |
Nucleic acid construct and use thereof
|
|
CA3257006A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
|
|
EP4522650A1
(en)
|
2022-05-13 |
2025-03-19 |
BioNTech SE |
Rna compositions targeting hiv
|
|
TW202409283A
(zh)
|
2022-05-13 |
2024-03-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
雙股dna組合物及相關方法
|
|
TW202400784A
(zh)
|
2022-05-13 |
2024-01-01 |
大陸商上海瑞宏迪醫藥有限公司 |
包含utr的核酸構建體及其應用
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
IL317018A
(en)
|
2022-05-23 |
2025-01-01 |
Logicbio Therapeutics Inc |
Garden treatment preparations and methods of using them
|
|
WO2023230295A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
Rna compositions for delivery of monkeypox antigens and related methods
|
|
KR20250028547A
(ko)
|
2022-05-25 |
2025-02-28 |
큐어백 에스이 |
대장균 FimH 항원성 폴리펩타이드를 인코딩하는 핵산 기반 백신
|
|
AU2023275780B2
(en)
|
2022-05-25 |
2026-03-05 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
EP4518845A1
(en)
|
2022-05-30 |
2025-03-12 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
|
TW202411426A
(zh)
|
2022-06-02 |
2024-03-16 |
美商斯奎柏治療公司 |
經工程化的2類v型crispr系統
|
|
KR20250031158A
(ko)
|
2022-06-03 |
2025-03-06 |
바이오-트립 비.브이. |
핵산 전달을 위한 다가 분자 기반 지질 나노입자
|
|
CA3258303A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Compositions of lipid nanoparticles and their uses
|
|
EP4536819A1
(en)
|
2022-06-07 |
2025-04-16 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
CN119998446A
(zh)
|
2022-06-07 |
2025-05-13 |
斯克里贝治疗公司 |
用于靶向pcsk9的组合物和方法
|
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
EP4558624A2
(en)
|
2022-07-18 |
2025-05-28 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
|
CA3260437A1
(en)
|
2022-07-20 |
2024-01-25 |
Beam Therapeutics Inc. |
NANOMATERIALS INCLUDING TRIOLS
|
|
JP2025525778A
(ja)
|
2022-08-01 |
2025-08-07 |
フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー |
免疫調節タンパク質及び関連方法
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
JP2025528195A
(ja)
|
2022-08-12 |
2025-08-26 |
ライフ エディット セラピューティクス,インコーポレイティド |
Rnaガイドヌクレアーゼ並びにその活性断片及びバリアント並びに使用方法
|
|
JP2025527531A
(ja)
|
2022-08-18 |
2025-08-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ユニバーサル非標的sirna組成物およびその使用方法
|
|
US20260055426A1
(en)
|
2022-08-19 |
2026-02-26 |
Generation Bio Co. |
CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024042236A1
(en)
|
2022-08-26 |
2024-02-29 |
Ethris Gmbh |
Stable lipid or lipidoid nanoparticle suspensions
|
|
EP4327829A1
(en)
|
2022-08-26 |
2024-02-28 |
Ethris GmbH |
Stabilization of lipid or lipidoid nanoparticle suspensions
|
|
KR20250056256A
(ko)
|
2022-08-31 |
2025-04-25 |
세일 바이오메디슨스, 인크. |
신규 이온화성 지질 및 지질 나노입자, 그리고 이의 사용 방법
|
|
WO2024053648A1
(ja)
|
2022-09-06 |
2024-03-14 |
国立大学法人九州大学 |
脂質ナノ粒子
|
|
EP4569113A1
(en)
|
2022-09-15 |
2025-06-18 |
Regeneron Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
|
EP4342460A1
(en)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipid nanoparticle with nucleic acid cargo
|
|
AU2023347320A1
(en)
|
2022-09-23 |
2025-04-10 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
EP4590331A1
(en)
|
2022-09-23 |
2025-07-30 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
|
CA3267942A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
COMPOSITIONS FOR THE ADMINISTRATION OF HEPATIC STAGE ANTIGENS AND ASSOCIATED METHODS
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
EP4593875A1
(en)
|
2022-09-26 |
2025-08-06 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
EP4594473A1
(en)
|
2022-09-27 |
2025-08-06 |
Resolution Therapeutics Limited |
Enhanced macrophages
|
|
WO2024071319A1
(en)
|
2022-09-28 |
2024-04-04 |
Okinawa Institute Of Science And Technology School Corporation |
Composition comprising isolated or enriched phosphoenolpyruvate or a salt thereof
|
|
WO2024073588A1
(en)
*
|
2022-09-28 |
2024-04-04 |
Board Of Regents, The University Of Texas System |
Respiratory dry powder delivery
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
IL319682A
(en)
|
2022-10-06 |
2025-05-01 |
BioNTech SE |
RNA complexes targeting claudin-18.2
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
JP7557915B2
(ja)
|
2022-10-18 |
2024-09-30 |
株式会社チップトン |
テイラー反応装置及びカプセル粒子の製造方法
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
CN120513299A
(zh)
|
2022-10-31 |
2025-08-19 |
旗舰创业创新第六有限责任公司 |
用于纯化多核糖核苷酸的组合物和方法
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
AR131008A1
(es)
|
2022-11-08 |
2025-02-05 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
EP4615517A1
(en)
|
2022-11-08 |
2025-09-17 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
EP4626444A2
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
AU2023406483A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
AU2023406321A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2024123134A1
(ko)
|
2022-12-09 |
2024-06-13 |
서울대학교산학협력단 |
B 세포 및 t 세포 내로 mrna를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이의 용도
|
|
KR20240087591A
(ko)
|
2022-12-09 |
2024-06-19 |
주식회사 나이벡 |
타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
|
|
WO2024125597A1
(en)
|
2022-12-14 |
2024-06-20 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
AU2023398825A1
(en)
|
2022-12-15 |
2025-06-26 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024133486A1
(en)
|
2022-12-20 |
2024-06-27 |
Universiteit Utrecht Holding B.V. |
Nucleic acid-lipid particles
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2024141955A1
(en)
|
2022-12-28 |
2024-07-04 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
CN120435314A
(zh)
|
2022-12-29 |
2025-08-05 |
波普瓦克斯私人有限公司 |
多靶疫苗和治疗剂
|
|
EP4628201A1
(en)
|
2023-01-04 |
2025-10-08 |
Inventage Lab Inc. |
Spiral-structured chip for preparing lipid nanoparticles, and method for preparing lipid nanoparticles by using same
|
|
EP4648794A2
(en)
|
2023-01-09 |
2025-11-19 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
EP4652262A1
(en)
|
2023-01-19 |
2025-11-26 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫調節組合物及相關方法
|
|
TW202449152A
(zh)
|
2023-02-09 |
2024-12-16 |
美商艾拉倫製藥股份有限公司 |
Reversir分子及其使用方法
|
|
KR20250151427A
(ko)
|
2023-02-13 |
2025-10-21 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
치료적 조성물을 위한 절단성 링커 함유 이온화 가능한 지질 및 지질 담체
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
TW202446956A
(zh)
|
2023-02-17 |
2024-12-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
包含經修飾的胞嘧啶的dna組成物
|
|
TW202438089A
(zh)
|
2023-02-17 |
2024-10-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
包含經修飾的尿嘧啶的dna組成物
|
|
AU2024233180A1
(en)
|
2023-03-08 |
2025-09-25 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2024190865A1
(ja)
|
2023-03-15 |
2024-09-19 |
ユナイテッド・イミュニティ株式会社 |
脂質粒子
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
WO2024192291A1
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
JP2026509462A
(ja)
|
2023-03-15 |
2026-03-19 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
ポリリボヌクレオチドを含む組成物及びその使用
|
|
EP4680595A2
(en)
|
2023-03-15 |
2026-01-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2024194767A1
(en)
|
2023-03-17 |
2024-09-26 |
BioNTech SE |
Automated drug production system
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
TW202444914A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
抑制子融合蛋白系統
|
|
AU2024242151A1
(en)
|
2023-03-29 |
2025-09-25 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of lpa
|
|
TW202444906A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
用於靶向pcsk9之組合物及方法
|
|
TW202444910A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
編碼casx之信使rna
|
|
WO2024209418A1
(en)
|
2023-04-07 |
2024-10-10 |
BioNTech SE |
Heating and cooling jacket for fluid vessels
|
|
EP4695393A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Modified trems, compositions, and related methods thereof
|
|
CN121219411A
(zh)
|
2023-04-12 |
2025-12-26 |
旗舰先锋创新Vi有限责任公司 |
用于在错义突变的校正中使用的trem
|
|
WO2024213740A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Vaccine mixing method, syringe and system
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
WO2024228150A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
EP4705481A2
(en)
|
2023-05-05 |
2026-03-11 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
EP4713453A1
(en)
|
2023-05-15 |
2026-03-25 |
nChroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024240962A1
(en)
|
2023-05-25 |
2024-11-28 |
Ethris Gmbh |
Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof
|
|
CN121666232A
(zh)
|
2023-05-31 |
2026-03-13 |
开普斯坦治疗公司 |
脂质纳米颗粒制剂和组合物
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
CN121311249A
(zh)
|
2023-06-22 |
2026-01-09 |
公益财团法人川崎市产业振兴财团 |
提高核酸的血中稳定性、提高靶向效率的方法
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
AU2024310564A1
(en)
|
2023-06-29 |
2025-11-27 |
BioNTech SE |
Modular multiplatform system for mrna drug production
|
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
|
TW202517669A
(zh)
|
2023-07-05 |
2025-05-01 |
日商武田藥品工業股份有限公司 |
用於A型血友病之基因療法的編碼表現增加之重組FVlll變異體的病毒載體
|
|
US20250135006A1
(en)
|
2023-07-07 |
2025-05-01 |
Pfizer Inc. |
Amphiphilic tlr7/8 adjuvants and uses thereof
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
WO2025015338A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
AU2024287308A1
(en)
|
2023-07-13 |
2025-12-18 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
CN120187853A
(zh)
|
2023-07-14 |
2025-06-20 |
云合智药(苏州)生物科技有限公司 |
用于抑制己酮糖激酶表达的RNAi剂及其应用
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024335A2
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025021083A1
(en)
*
|
2023-07-24 |
2025-01-30 |
National Institute Of Biological Sciences, Beijing |
Lipid nanoparticle compositions for localized treatment of skin diseases
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024486A2
(en)
|
2023-07-25 |
2025-01-30 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
TW202519509A
(zh)
|
2023-08-01 |
2025-05-16 |
德商拜恩技術股份公司 |
可離子化硫脂質及其用途
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
NL2035538B1
(en)
|
2023-08-03 |
2025-02-18 |
Univ Eindhoven Tech |
Lipid-like copolymers and method of producing these and the use thereof, pharmaceutical compositions comprising said copolymers, and the use of said compositions.
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
CN121605192A
(zh)
|
2023-08-04 |
2026-03-03 |
阿尔尼拉姆医药品有限公司 |
用于治疗ctnnb1-相关病症的方法和组合物
|
|
US12162927B1
(en)
|
2023-08-09 |
2024-12-10 |
Wyvern Pharmaceuticals Inc. |
Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025045767A1
(en)
|
2023-08-25 |
2025-03-06 |
Ethris Gmbh |
Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
CN121752256A
(zh)
|
2023-09-01 |
2026-03-27 |
诺沃阿克有限责任公司 |
具有核酸负载物和可电离脂质的脂质纳米颗粒
|
|
AU2024335327A1
(en)
|
2023-09-01 |
2026-03-26 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025051994A1
(en)
|
2023-09-07 |
2025-03-13 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
US20250268826A1
(en)
|
2023-09-18 |
2025-08-28 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025072672A2
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
WO2025068489A1
(en)
|
2023-09-27 |
2025-04-03 |
Resolution Therapeutics Limited |
Therapeutic macrophages
|
|
WO2025072699A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Aminoglycosides for delivery of agents to the kidney
|
|
WO2025072293A1
(en)
|
2023-09-27 |
2025-04-03 |
Scribe Therapeutics Inc. |
Optimized mrnas encoding casx proteins
|
|
WO2025072713A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Polymyxins for delivery of agents to the kidney
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
US20250162981A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
US12195747B1
(en)
|
2023-11-22 |
2025-01-14 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12435338B2
(en)
|
2023-11-22 |
2025-10-07 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12522830B2
(en)
|
2023-11-22 |
2026-01-13 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
US12559754B2
(en)
|
2023-11-22 |
2026-02-24 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2025114520A1
(en)
|
2023-12-01 |
2025-06-05 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025129201A1
(en)
|
2023-12-15 |
2025-06-19 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025144938A1
(en)
|
2023-12-26 |
2025-07-03 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
WO2025140551A1
(en)
|
2023-12-29 |
2025-07-03 |
Neuro3 Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
KR102716110B1
(ko)
|
2024-01-19 |
2024-10-15 |
(주) 멥스젠 |
다양한 크기를 갖는 지질나노입자 제조용 미세유체장치 및 이를 이용한 제조방법
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
TW202546224A
(zh)
|
2024-02-12 |
2025-12-01 |
美商生命編輯治療學公司 |
新穎的rna引導之核酸酶及用於聚合酶編輯之蛋白質
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
US12281311B1
(en)
|
2024-02-20 |
2025-04-22 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12416020B2
(en)
|
2024-02-20 |
2025-09-16 |
Wyvern Pharmaceuticals Inc. |
Plasmid encoding a TLR3 and Fc fusion protein
|
|
US12522831B2
(en)
|
2024-02-20 |
2026-01-13 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12540324B2
(en)
|
2024-02-20 |
2026-02-03 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
TW202543583A
(zh)
|
2024-03-01 |
2025-11-16 |
加拿大商阿奎特斯醫療公司 |
用於將治療劑包覆於脂質奈米顆粒中之材料及方法
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025199231A2
(en)
|
2024-03-20 |
2025-09-25 |
Vertex Pharmaceuticals Incorporated |
Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2025202287A1
(en)
|
2024-03-26 |
2025-10-02 |
Resolution Therapeutics Limited |
Method of producing macrophages
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025219570A1
(en)
|
2024-04-17 |
2025-10-23 |
Johannes Kepler Universität Linz |
Composition for inhibiting protein translocation and methods using the same
|
|
KR20250157196A
(ko)
*
|
2024-04-26 |
2025-11-04 |
한국과학기술원 |
핵산 분자의 흡입 전달용 지질 나노복합체
|
|
WO2025228975A1
(en)
|
2024-04-29 |
2025-11-06 |
BioNTech SE |
Particles, compositions and methods
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2025259747A2
(en)
|
2024-06-12 |
2025-12-18 |
Alnylam Pharmaceuticals, Inc. |
Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
WO2026003754A1
(en)
|
2024-06-25 |
2026-01-02 |
Life Edit Therapeutics, Inc. |
Novel reverse transcriptases and uses thereof
|
|
WO2026006577A1
(en)
|
2024-06-26 |
2026-01-02 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026022652A1
(en)
|
2024-07-22 |
2026-01-29 |
Waters Technologies Corporation |
Methods for analyzing lipid nanoparticles and uses thereof
|
|
WO2026024954A2
(en)
|
2024-07-24 |
2026-01-29 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
US12570983B2
(en)
|
2024-08-30 |
2026-03-10 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
WO2026055461A1
(en)
|
2024-09-05 |
2026-03-12 |
Aperture Therapeutics, Inc. |
Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026057626A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having multiple enzymatically active domains
|
|
WO2026057625A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having a chap domain with engineered active site
|
|
US12480129B1
(en)
|
2024-09-17 |
2025-11-25 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12509688B1
(en)
|
2024-09-17 |
2025-12-30 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12486506B1
(en)
|
2024-09-20 |
2025-12-02 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12480121B1
(en)
|
2024-09-20 |
2025-11-25 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12545917B1
(en)
|
2024-09-20 |
2026-02-10 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12480123B1
(en)
|
2024-09-20 |
2025-11-25 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12503702B1
(en)
|
2024-09-25 |
2025-12-23 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12416021B1
(en)
|
2024-10-11 |
2025-09-16 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of proteins
|
|
US12416022B1
(en)
|
2024-10-29 |
2025-09-16 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of proteins
|
|
US12428654B1
(en)
|
2024-10-29 |
2025-09-30 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of proteins
|
|
US12509694B1
(en)
|
2024-12-12 |
2025-12-30 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12529059B1
(en)
|
2024-12-12 |
2026-01-20 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12553046B1
(en)
|
2025-02-11 |
2026-02-17 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12565652B1
(en)
|
2025-03-27 |
2026-03-03 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
US12497618B1
(en)
|
2025-09-09 |
2025-12-16 |
Wyvern Pharmaceuticals Inc. |
Composition for regulating production of interfering ribonucleic acid
|
|
CN121466311A
(zh)
*
|
2026-01-09 |
2026-02-06 |
羿美诚健(上海)生物医药有限公司 |
一种脂质组合物及其在核酸递送中的应用
|